Biological
UCAR-T cells
UCAR-T cells is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph early_phase_1
1
33%
Ph not_applicable
1
33%
Ph phase_1
1
33%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Active, not recruiting1
unknown1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Early Phase 11 (33.3%)
Phase 11 (33.3%)
N/A1 (33.3%)
Trials by Status
active_not_recruiting133%
unknown133%
not_yet_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingearly_phase_1
UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases
NCT07410377
active_not_recruitingnot_applicable
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT07155369
unknownphase_1
Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
NCT05639179
Clinical Trials (3)
Showing 3 of 3 trials
NCT07410377Early Phase 1
UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases
NCT07155369Not Applicable
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT05639179Phase 1
Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3